Ataxia UK has been talking with Minoryx therapeutics, a company focusing on developing new drugs for rare conditions, and we are delighted with this new trial being announced. The trial will be a phase 2 double blind placebo-controlled trial testing the effect of a drug called MIN-2 a new selective PPAR gamma agonist. See more information in the press release here.